{"title":"诱导治疗后连续正电子发射断层扫描作为胸腺癌患者预后结果的预测因子。","authors":"Yudai Miyashita, Takashi Kanou, Tomomi Isono, Hiroto Ishida, Hideki Nagata, Teiko Sakurai, Kenji Kimura, Eriko Fukui, Toru Kimura, Naoko Ose, Tadashi Watabe, Yasushi Shintani","doi":"10.1007/s00595-024-02954-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the role of <sup>18</sup>F-fluorodeoxy glucose-positron emission tomography/computed tomography (FDG-PET/CT) to assess pathological response and prognosis after induction therapy in patients with thymic carcinoma.</p><p><strong>Methods: </strong>The subjects of this retrospective study were 18 patients with thymic carcinoma who underwent FDG-PET, before and after induction therapy. We measured the maximum standardized uptake value (SUVmax) of the tumor and analyzed the correlation between the change in SUVmax and pathological response or recurrence.</p><p><strong>Results: </strong>Induction therapy led to a reduction in both the tumor size and SUVmax in most patients. A strong correlation (Pearson coefficient = 0.90, p < 0.0001) was observed between the changes in tumor size and SUVmax. Although the SUVmax and tumor size showed no association with the pathological response, an SUVmax change > 50% predicted lower recurrence rates (p = 0.03).</p><p><strong>Conclusion: </strong>Changes in the SUVmax following induction therapy may serve as a valuable predictor of recurrence in patients with thymic carcinoma. This finding highlights the potential of FDG-PET as a tool for patient monitoring and prognostication of this rare subset of carcinomas. Further studies are warranted to validate these results and standardize the FDG-PET protocols for optimal clinical use.</p>","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serial positron-emission tomography after induction therapy as a predictor of prognostic outcomes for patients with thymic carcinoma.\",\"authors\":\"Yudai Miyashita, Takashi Kanou, Tomomi Isono, Hiroto Ishida, Hideki Nagata, Teiko Sakurai, Kenji Kimura, Eriko Fukui, Toru Kimura, Naoko Ose, Tadashi Watabe, Yasushi Shintani\",\"doi\":\"10.1007/s00595-024-02954-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate the role of <sup>18</sup>F-fluorodeoxy glucose-positron emission tomography/computed tomography (FDG-PET/CT) to assess pathological response and prognosis after induction therapy in patients with thymic carcinoma.</p><p><strong>Methods: </strong>The subjects of this retrospective study were 18 patients with thymic carcinoma who underwent FDG-PET, before and after induction therapy. We measured the maximum standardized uptake value (SUVmax) of the tumor and analyzed the correlation between the change in SUVmax and pathological response or recurrence.</p><p><strong>Results: </strong>Induction therapy led to a reduction in both the tumor size and SUVmax in most patients. A strong correlation (Pearson coefficient = 0.90, p < 0.0001) was observed between the changes in tumor size and SUVmax. Although the SUVmax and tumor size showed no association with the pathological response, an SUVmax change > 50% predicted lower recurrence rates (p = 0.03).</p><p><strong>Conclusion: </strong>Changes in the SUVmax following induction therapy may serve as a valuable predictor of recurrence in patients with thymic carcinoma. This finding highlights the potential of FDG-PET as a tool for patient monitoring and prognostication of this rare subset of carcinomas. Further studies are warranted to validate these results and standardize the FDG-PET protocols for optimal clinical use.</p>\",\"PeriodicalId\":22163,\"journal\":{\"name\":\"Surgery Today\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00595-024-02954-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-024-02954-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Serial positron-emission tomography after induction therapy as a predictor of prognostic outcomes for patients with thymic carcinoma.
Purpose: To investigate the role of 18F-fluorodeoxy glucose-positron emission tomography/computed tomography (FDG-PET/CT) to assess pathological response and prognosis after induction therapy in patients with thymic carcinoma.
Methods: The subjects of this retrospective study were 18 patients with thymic carcinoma who underwent FDG-PET, before and after induction therapy. We measured the maximum standardized uptake value (SUVmax) of the tumor and analyzed the correlation between the change in SUVmax and pathological response or recurrence.
Results: Induction therapy led to a reduction in both the tumor size and SUVmax in most patients. A strong correlation (Pearson coefficient = 0.90, p < 0.0001) was observed between the changes in tumor size and SUVmax. Although the SUVmax and tumor size showed no association with the pathological response, an SUVmax change > 50% predicted lower recurrence rates (p = 0.03).
Conclusion: Changes in the SUVmax following induction therapy may serve as a valuable predictor of recurrence in patients with thymic carcinoma. This finding highlights the potential of FDG-PET as a tool for patient monitoring and prognostication of this rare subset of carcinomas. Further studies are warranted to validate these results and standardize the FDG-PET protocols for optimal clinical use.
期刊介绍：
Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it").
The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
